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Abstract
Thyrotoxic periodic paralysis is a disease characterized by recurrent episodes of paralysis and
hypokalemia during a thyrotoxic state. Thyrotoxic periodic paralysis is a common complication of
hyperthyroidism in Asian populations, but can affect other ethnic groups as well. Due to population
mobility, Thyrotoxic periodic paralysis is increasingly common in Western countries. Early diagnosis
and prompt treatment of the thyrotoxic state and potassium supplementation prevent life-
threatening complications associated with hypokalemia and muscle weakness. We present a young
Turkish man who developed acute flaccid paralysis after receiving pulse prednisolone therapy for
treatment of Pityriasis versicolor. His muscle strength and serum potassium fully recovered after
potassium replacement and treatment of the thyrotoxic state which was a consequence of underlying
Graves’ disease.
Introduction
Acute tetraparesis is a neurological emergency which
requires immediate diagnostic workup. Differential diag-
nosis of acute tetraparesis includes paraplegia caused by
trauma, Guillain-Barré syndrome, ischemia, myasthenia
gravis, inflammation, tumor, dissociative paralysis and
periodic paralysis [1]. The heterogeneous group of muscle
diseases known as periodic paralyses (PP) is characterized
by episodic, sudden onset, flaccid paralysis of a single,
several or all skeletal muscles with usually complete
recovery between the attacks. Commonly, PPs are divided
into primary, due to a genetic defect with familial or
sporadic occurrence, and secondary forms due to drugs,
suprarenal gland disease and misuse of laxatives or
thiazide diuretics [2]. One primary form is the thyrotoxic
periodic paralysis (TPP) which is characterized by recur-
rent episodes of paralysis and hypokalemia in the setting
of thyrotoxicosis.
Case presentation
A 32-year-old Turkish man was admitted to the emergency
department because of severe intrascapular back pain, an
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Bilateral proximal muscle weakness of the lower extremi-
ties had started approximately 4 hours before admission
and progressed rapidly. Three hours after appearance of
the weakness the patient collapsed and was unconscious
for 2 minutes, accompanied by urinary incontinence. No
seizure was observed. After regaining consciousness he
complained about severe intrascapular back pain, stabbing
in nature without radiation. Initially the blood pressure
was 80/60 mmHg, the heart rate was 100 bpm and the
blood glucose level was 223 mg/dl. Emergency treatment
with rapid infusion of cristalloid fluids was started and the
patient was transferred to the hospital. When the patient
arrived at the emergency department the blood pressure
was 110/60 mmHg and the heart rate was 120 bpm. On
his trunk and arms were confluating erythematous patches
which appeared3 days ago.Body temperature was normal.
His muscle strength was found to be 2/5 on the MRC scale
(Medical Research Council Paralysis Scale) in both lower
extremities and 3/5 in both upper extremities. The deep
tendon reflexes were somewhat diminished, otherwise
neurological and physical examination were normal. He
smoked 50 cigarettes a day and his alcohol intake was
moderate. The family history was negative for cardiovas-
cular disease. Beside nephrectomy after traumatic kidney
rupture in childhood no relevant previous disease was
present and no previous muscle weakness was noticed.
However he reported that he consulted his GP the same
morning for treatment of the erythematous patches. The
GP gave him a pulse i.v. corticosteroid infusion (250 mg
prednisolone).
The electrocardiogram revealed a sinus tachycardia of
118 bpm, a prolonged QTc interval, ST-segment depres-
sions in all leads and T-U-wave complexes in the lateral
leads (Figure 1). To rule out an aortic dissection a contrast
computed tomography of the chest was performed
immediately after admission, however no structural
abnormality was detected. The only noticeable finding
was a severely reduced cardiac output, recognized at the
delayed contrast of the arteries. The biochemical labora-
tory analyses were within normal limits, except of a serum
potassium level of 1.2 mmol/l [Norm 3.5-5.0 mmol/l],
a ph of 7.26 [Norm 7.37-7.45], a bicarbonate level of
16.9 mmol/l [Norm 22-30 mmol/l], a base excess of
-9.0 mmol/l [Norm -2.0-3.0 mmol/l] and a chloride level
of 116 mmol/l [Norm 95-105 mmol/l], a TSH (Thyroidea
stimulating hormone) level of <0.01 µIU/ml [Norm
0.27-4.20 µIU/ml], a fT3 (free trijodthyronine) level of
10.82 pg/ml [Norm 2.53-4.34 pg/ml] and a fT4 (free
thyroxine) level of 3.2 pg/ml [Norm 0.9-1.7 pg/ml]. After
receiving the laboratory results TPP was diagnosed and
intravenous administration of potassium chloride was
begun. Because of prior contrast medium exposure a
therapy with methimazol and perchlorate was started.
After administration of 30 mmol of potassium chloride
within 3 hours, the patient got serious cardiac bradyar-
rhythmias followed by an asystolia which required
mechanical reanimation for a short period of time. The
serum potassium level at that time was 1.6 mmol/l.
During the following 4 hours the patient developed a
rebound hyperkalemia with a potassium level of 9 mmol/l
which however did not induce any complications and
lasted for 60 minutes despite any medical interventions.
After intravenous administration of overall 90 mmol of
potassium chloride the patients muscle strength and
serum potassium were fully restored within 12 hours.
Further laboratory diagnostics showed a high titre
of thyrotropin-receptor antibodies, [7,4 IU/l (Norm
<1,0 IU/l)] and a high titre of thyroid peroxidase anti-
bodies [540 IU/ml (Norm <34 IU/ml)], both providing
evidence of Graves’ disease [3]. Ultrasound examination
revealed a normal sized thyroid gland with an inhomo-
geneous pattern. The skin changes were diagnosed as
Pityriasis versicolor.
Discussion
This case report highlights an unusual presentation of a
patient with symptoms consistent with those seen in
patients with an aortic dissection, where further diagnos-
tics however revealed an initial manifestation of TPP
which was induced by intravenous pulse prednisolone
therapy. TPP is a well-known complication of thyrotox-
icosis in Asian populations. The overall incidence of TPP
among patients with hyperthyroidism in China and Japan
is 1.8 and 1.9% respectively [4-5], whereas it is 0.1-0.2%
among North American population with thyrotoxicosis
[6]. Recently Cesur et al. analyzed 40 cases of TPP within
the Turkish population, where most of the population are
Figure 1. Electrocardiogram showing sinus tachycardia,
a prolonged QTc interval, ST-segment depressions in all
leads and T-U-wave complexes in the lateral leads.
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Mediterranid extraction [7]. This report and other reports
from the Mediterranean regions indicate the tendency to
find TPP in the Mediterranid ethnicity other than the
remaining Caucasoid subspecies. Despite the woman
predominance of hyperthyroidism, TPP occurs more
commonly in men at a ratio of 20 : 1. The majority of
thyrotoxic patients associated with TPP is due to Graves’
disease, while other conditions have been reported [8].
TPP is characterized by recurrent, transient episodes of
muscle weakness to complete flaccid paralysis in the
setting of a low serum potassium level and biochemical
evidence of thyrotoxicosis, low TSH along with elevated
fT4 orfT3, asobserved inour patient. Deeptendon reflexes
are reduced or absent. Findings of thyrotoxicosis may be
subtle or even clinical silent [9]. The pathogenesis of TPP
remains still unclear. Hypokalemia is the consequence of a
rapid and massive shift of potassium from the extracellular
into the intracellular compartment, related to increased
sodium-potassium-adenosine triphosphate (Na/
K-ATPase) pump-activity [8]. Patients with TPP have
significantly higher Na/K-ATPase pump number and
activity than thyrotoxic patients without TPP and the
activity returns to normal when their thyroid function is
controlled. Correction of the underlying thyrotoxic state
aborts the attacks, but they can recur with the return of
thyrotoxicosis [4]. It has been shown that thyroid
hormones increase via transcriptional and posttranscrip-
tional mechanisms Na/K-ATPase activity in skeletal
muscles. Apart from direct stimulation by thyroid hor-
mones, catecholamine and the enhanced b-adrenergic
response in thyrotoxicosis further increases the activity of
the Na/K-ATPase in skeletal muscle [8]. Furthermore there
are indications that insulin plays an important role in the
development of TPP and it could be demonstrated that
serum insulin levels are elevated prior to the attack.
Insulin-response sequences are present in the upstream
region of Na/K-ATPase genes in skeletal muscle and
insulin has been shown to stimulate Na/K-ATPase activity
which may explain the association of TPP attacks with
carbohydrate-rich meals. Other precipitating factors for an
attack are ingestion of alcohol or strenuous exercise [2].
Overall it appears that patients with TPP have an under-
lying predisposition for activation of Na/K-ATPase activity,
either directly by thyroid hormone or indirectly via
adrenergic stimulation, insulin or exercise. To determine
whether this predisposition is genetically associated
rigorous attempts have been devoted to the search of the
gene mutation of ion channels in TPP. The pathogenesis of
FHPP (Familial Hypokalemic Periodic Paralysis), another
entity of the primary periodic paralyses which is frequently
experienced in Caucasian countries [10], has been
elucidated and in most cases the abnormal gene is the
alpha-1 subunit of the dihydropyridine-sensitive calcium
channel in skeletal muscle (CACN1AS). In others it
appears to be due to mutations in the skeletal muscle
sodium channel (SCN4A) or the potassium channel
(KCNE3) [11]. In TPP however, to date only certain
single-nucleotide polymorphisms (SNiPs) of CACN1AS
were associated with TPP in southern Chinese. Those
SNiPs may provide a risk to the attack of TPP [12].
Glucocorticoids may induce hypokalemia from a transcel-
lular potassium shift caused by an increased Na/K-ATPase
pool in skeletal muscles and steroid-induced hyperinsuli-
nemia and hyperglycemia which we also observed in our
patient [13-15]. Current treatment recommendations
involve treating the underlying hyperthyroid state and
supplementation with potassium chloride (KCL) to pre-
vent major cardiopulmonary complications. The dose of
KCL required varies between 40 and 200 mmol. However
excessive potassium replacement may result in rebound
hyperkalemia during recovery of the paralysis when
potassium is released from cells as the paralysis subsides,
posing another risk of cardiac arrhythmia [8]. Furthermore
a therapy with nonselective b-blockers has been reported,
based on the implication of hyperadrenergic activity in the
pathogenesis of TPP [8]. Whether the combination of low
dose KCL and nonselective b-blockers is the treatment of
choice in facilitating the recovery and reducing rebound
hyperkalemia awaits further study in future.
In conclusion, TPP may be seen not only in the Asian
population, but also in the Turkish and also in the
Caucasian populations, especially in the Mediterranid. It is
important to be aware of features of TPP, although it is
crucial to emphasize that other diagnostics like computed
tomography, magnetic resonance imaging or cerebro-
spinal fluid puncture must not be delayed to exclude
other serious diseases. Current treatment recommenda-
tions involve treating the underlying hyperthyroid state,
KCL supplementation which should be given as small as
possible (<10 mmol/hr) to avoid rebound hyperkalemia
unless there are cardiopulmonary complications and
b-blockade.
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